SUMMIT, NJ and CAMBRIDGE, Mass. - 01 Nov 2016: Celgene Corporation (NASDAQ: CELG) and IBM Watson Health (NYSE: IBM) today announced a collaboration to co-develop IBM Watson for Patient Safety, a new offering that aims to enhance pharmacovigilance methods used to collect, assess, monitor, and report adverse drug reactions. The new offering will run on the Watson Health Cloud.
IBM News room - 2016-11-01 Celgene and IBM Watson Health Forge Collaboration Designed to Transform Patient Safety Monitoring - United States
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.